Provided by Tiger Fintech (Singapore) Pte. Ltd.

Intra-Cellular Therapies

131.96
+0.03900.03%
Volume:1.34M
Turnover:177.39M
Market Cap:14.03B
PE:-182.24
High:131.98
Open:131.92
Low:131.90
Close:131.92
Loading ...

Jefferies profit misses estimates as bond trading, equity underwriting weaken

Reuters
·
27 Mar

Here's How to Play JNJ Stock as it Announces $55B US Investment Plan

Zacks
·
24 Mar

BRIEF-Intra-Cellular Therapies stockholder filed lawsuit against co, board in NY Supreme Court

Reuters
·
19 Mar

Intra-Cellular Therapies- on Feb 26, Stockholder Filed Lawsuit Against Co and Board in New York Supreme Court - SEC Filing

THOMSON REUTERS
·
19 Mar

Intra-Cellular Therapies Inc - Believes Lawsuit Claims Are Without Merit

THOMSON REUTERS
·
19 Mar

Is Intra-Cellular Therapies, Inc. (ITCI) a Best Biotech Stock According to Billionaires?

Insider Monkey
·
18 Mar

Big Pharma Walked Away From Mental Health. Why Some Are Coming Back. -- Heard on the Street -- WSJ

Dow Jones
·
14 Mar

JNJ Halts Development of Depression Drug Over Efficacy Concerns

Zacks
·
08 Mar

Johnson & Johnson Stops Late-Stage Depression Study Over 'Insufficient Efficacy'

Benzinga
·
07 Mar

Intra-Cellular Therapies, Inc. (ITCI): Among the Best Psychedelic Stocks to Buy in 2025

Insider Monkey
·
02 Mar

Intra-Cellular Therapies Reports Strong 2024 Growth

TIPRANKS
·
25 Feb

ITCI Q4 Loss Wider Than Expected, Revenues Top on Higher Caplyta Sales

Zacks
·
25 Feb

Intra-Cellular Therapies Cut to Neutral From Outperform by Mizuho

Dow Jones
·
24 Feb

Mizuho Downgrades Intra-Cellular Therapies to Neutral From Outperform, Lowers Price Target to $132 From $140

MT Newswires Live
·
24 Feb

Analysts Have Conflicting Sentiments on These Healthcare Companies: Intra-Cellular Therapies (ITCI), Axsome Therapeutics (AXSM) and Merck & Company (MRK)

TIPRANKS
·
24 Feb

Hold Rating on Intra-Cellular Therapies Amid sNDA Progress and J&J Acquisition Prospects

TIPRANKS
·
22 Feb